All-in-One Mammalian Display (AOMD): 

In addition to traditional methods for developing polyclonal and monoclonal antibodies, we offer a unique solution: the All-in-One-Mammalian Display (AOMD) platform. This platform employs retrovirus to create a scFV fragment library in mammalian cells, allowing us to identify antigens-specific antibodies with high potential for CAR-T cell therapy or therapeutic bi-specific antibody use. We can also introduce mutations into the CDRs of the antibodies within the cells for further maturation selection. By leveraging this innovative platform, we can accelerate your drug discovery process.